TitleEmerging epigenetic-modulating therapies in lymphoma.
Publication TypeJournal Article
Year of Publication2019
AuthorsSermer, David, Pasqualucci Laura, Wendel Hans-Guido, Melnick Ari, and Younes Anas
JournalNat Rev Clin Oncol
Date Published2019 Aug
KeywordsAntineoplastic Agents, Epigenesis, Genetic, Humans, Lymphoma

<p>Despite considerable advances in the treatment of lymphoma, the prognosis of patients with relapsed and/or refractory disease continues to be poor; thus, a continued need exists for the development of novel approaches and therapies. Epigenetic dysregulation might drive and/or promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with haematological malignancies. In this Review, we provide a concise overview of the most promising epigenetic therapies for the treatment of lymphomas, including inhibitors of histone deacetylases (HDACs), DNA methyltransferases (DNMTs), enhancer of zeste homologue 2 (EZH2), bromodomain and extra-terminal domain proteins (BETs), protein arginine N-methyltransferases (PRMTs) and isocitrate dehydrogenases (IDHs), and highlight the most promising future directions of research in this area.</p>

Alternate JournalNat Rev Clin Oncol
PubMed ID30837715
PubMed Central IDPMC6650343
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
P50 CA192937 / CA / NCI NIH HHS / United States
R01 CA172492 / CA / NCI NIH HHS / United States
R35 CA220499 / CA / NCI NIH HHS / United States